The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%
|
---|---|
Published in |
Frontiers in Pharmacology, January 2022
|
DOI | 10.3389/fphar.2021.803626 |
Pubmed ID | |
Authors |
Qiao Liu, Zhen Zhou, Xia Luo, Lidan Yi, Liubao Peng, Xiaomin Wan, Chongqing Tan, Xiaohui Zeng |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 11 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Other | 2 | 18% |
Student > Ph. D. Student | 1 | 9% |
Unspecified | 1 | 9% |
Researcher | 1 | 9% |
Student > Bachelor | 1 | 9% |
Other | 0 | 0% |
Unknown | 5 | 45% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 2 | 18% |
Biochemistry, Genetics and Molecular Biology | 1 | 9% |
Unspecified | 1 | 9% |
Chemistry | 1 | 9% |
Economics, Econometrics and Finance | 1 | 9% |
Other | 0 | 0% |
Unknown | 5 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2022.
All research outputs
#18,571,001
of 23,001,641 outputs
Outputs from Frontiers in Pharmacology
#8,352
of 16,310 outputs
Outputs of similar age
#363,039
of 504,536 outputs
Outputs of similar age from Frontiers in Pharmacology
#576
of 1,190 outputs
Altmetric has tracked 23,001,641 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,310 research outputs from this source. They receive a mean Attention Score of 5.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 504,536 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,190 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.